Search	Query	Items
Pubmed	(up to 20 December 2017)	
1	("antimalarials"[Pharmacological Action] OR	81666
	"antimalarials"[MeSH Terms] OR "antimalarials"[All Fields])	
2	("hydroxychloroquine"[MeSH Terms] OR	3977
	"hydroxychloroquine"[All Fields])	
3	("chloroquine diphosphate"[Supplementary Concept] OR	530
	"chloroquine diphosphate"[All Fields])	
4	("chloroquine"[MeSH Terms] OR "chloroquine"[All Fields])	22064
5	1 OR 2 OR 3 OR 4	86811
6	("heart failure"[MeSH Terms] OR ("heart"[All Fields] AND	218047
	"failure"[All Fields]) OR "heart failure"[All Fields])	
7	("death, sudden"[MeSH Terms] OR ("death"[All Fields] AND	54212
	"sudden"[All Fields]) OR "sudden death"[All Fields] OR	
	("sudden"[All Fields] AND "death"[All Fields]))	
8	("myocardial infarction"[MeSH Terms] OR ("myocardial"[All	233673
	Fields] AND "infarction"[All Fields]) OR "myocardial	
	infarction"[All Fields] OR ("heart"[All Fields] AND "attack"[All	
	Fields]) OR "heart attack"[All Fields])	
9	("myocardial ischaemia"[All Fields] OR "myocardial	448821
	ischemia"[MeSH Terms] OR ("myocardial"[All Fields] AND	

Supplementary table 1 Detailed search strategy in Pubmed

"ischemia"[All Fields]) OR "myocardial ischemia"[All Fields] OR
"coronary artery disease"[MeSH Terms] OR ("coronary"[All
Fields] AND "artery"[All Fields] AND "disease"[All Fields]) OR
"coronary artery disease"[All Fields] OR ("myocardial"[All
Fields] AND "ischemia"[All Fields]))

- 10 ("heart diseases"[MeSH Terms] OR ("heart"[All Fields] AND 1107971"diseases"[All Fields]) OR "heart diseases"[All Fields])
- 11 ("acute coronary syndrome"[MeSH Terms] OR ("acute"[All 26741
 Fields] AND "coronary"[All Fields] AND "syndrome"[All Fields])
 OR "acute coronary syndrome"[All Fields])
- 12 ("death, sudden, cardiac"[MeSH Terms] OR ("death"[All Fields] 30984
 AND "sudden"[All Fields] AND "cardiac"[All Fields]) OR
 "cardiac sudden death"[All Fields] OR ("sudden"[All Fields] AND
 "cardiac"[All Fields] AND "arrest"[All Fields]) OR "sudden
 cardiac arrest"[All Fields])
- 13 ("ischaemic heart disease"[All Fields] OR "myocardial 463593
 ischemia"[MeSH Terms] OR ("myocardial"[All Fields] AND
 "ischemia"[All Fields]) OR "myocardial ischemia"[All Fields] OR
 ("ischemic"[All Fields] AND "heart"[All Fields] AND
 "disease"[All Fields]) OR "ischemic heart disease"[All Fields] OR
 "coronary artery disease"[MeSH Terms] OR ("coronary"[All
 Fields] AND "artery"[All Fields] AND "disease"[All Fields]) OR

"coronary artery disease"[All Fields] OR ("ischemic"[All Fields] AND "heart"[All Fields] AND "disease"[All Fields]))

- 14 ("coronary disease"[MeSH Terms] OR ("coronary"[All Fields] 297136
 AND "disease"[All Fields]) OR "coronary disease"[All Fields] OR
 ("coronary"[All Fields] AND "heart"[All Fields] AND
 "disease"[All Fields]) OR "coronary heart disease"[All Fields])
- 15 ("angina pectoris"[MeSH Terms] OR ("angina"[All Fields] AND 48337"pectoris"[All Fields]) OR "angina pectoris"[All Fields])
- 16 (("heart"[MeSH Terms] OR "heart"[All Fields] OR "coronary"[All 33749Fields]) AND revascularization [All Fields])
- 17 ("stroke"[MeSH Terms] OR "stroke"[All Fields]) 280971
- 18 ("cardiovascular diseases"[MeSH Terms] OR 2217214
 ("cardiovascular"[All Fields] AND "diseases"[All Fields]) OR
 "cardiovascular diseases"[All Fields])
- 19 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 2436156 16 OR 17 OR 18

|--|

Study	All CVD		Adjusted factors in multivariate analysis	Definitions of CVD
	Events occurred during follow-up period	RR (95% CI) (or OR [95% CI])		
Mok, 2007,	42	2.03 (0.74-5.60)	Age, gender, smoking, hypertension, diabetes mellitus,	Cerebrovascular accident (CVA or
China ²⁰			obesity, hypercholesterolemia, chronic renal	stroke), transient ischemic attack, angina pectoris,
			insufficiency, SLE; and use of high-dose prednisolone	acute myocardial infarction, digital gangrene,
			cyclophosphamide, azathioprine, mycophenolate	intermittent
			mofetil, calcineurin inhibitors, aspirin, statins,	claudication, amaurosis fugax or retinal artery
			angiotensin-converting enzyme inhibitors, and	occlusion
			angiotensin II-receptor blockers	
Siso, 2008, Spain ²⁷	28	0.58 (0.21-1.62)	Unadjusted	Cardiovascular events, including cerebrovascular
				accident or ischemic heart disease
Gustafsson, 2009,	24	1.01 (0.32-2.67)	Age	Myocardial infarction, angina pectoris, cerebral
Sweden ¹⁸				infarction, transitory ischemic attacks, intermittent
				claudication or peripheral arterial
				thrombosis/embolus, death due to myocardial
				infarction, heart failure, sudden death, cerebral
				infarction, generalized atherosclerosis as stated by
				death certificate
Nikpour, 2011,	86	0.50 (0.31-0.79)	Age, gender, disease duration, disease-activity score,	Coronary artery disease events including angina
Canada ²¹			anti-phospholipid antibodies, diabetes, smoking and	pectoris, myocardial infarction, and sudden cardiac
			medications including corticosteroids,	death

Supplementary table 2 Detailed outcomes of studies on chloroquine/hydroxychloroquine and cardiovascular disease (CVD)


Study	All CVD		Adjusted factors in multivariate analysis	Definitions of CVD
	Events occurred during follow-up period	RR (95% CI) (or OR [95% CI])		
Magder, 2012,	134	0.77 (0.54-1.12)	immunosuppressives, antihypertensives, and lipid- lowering therapy (statins) Age, gender, year before 1993, blood pressure, serum	Myocardial infarction, thrombotic stroke, clinically
USA ¹⁹			cholesterol, diabetes mellitus, SELENA-SLEDAI, anti- dsDNA, serum creatinine, low hematocrit, history of hemolytic anemia, history of lupus anticoagulant and current corticosteroid dose	definite angina, percutaneous coronary intervention, a coronary bypass procedure, or claudication
Arnaud, 2015, Argentina, France, Greece,	-	0.77 (0.32-1.84)	Center effect	Arterial thrombosis
Italy and Spain ¹⁴				
Sharma, 2016, USA ²⁴	102	0.60 (0.41-0.94)	Age, gender, body mass index, low-density lipoprotein, smoking, diabetes, hypertension, anti–cyclic citrullinated peptide antibodies, rheumatoid factor, erythrocyte sedimentation rate, methotrexate, and tumor necrosis factor α inhibitor use	A composite of Coronary artery disease (myocardial infarction, unstable angina, or cardiac revascularization procedure), sudden death due to cardiac etiology, stroke, transient ischemic attack or peripheral arterial disease with arterial revascularization procedure
Hsu, 2017, China ²⁸	35	0.58 (0.29-1.15)	Propensity score matching (age, gender, comorbidities, medications, overlapping immune diseases, number of admissions due to SLE and year of index date)	Acute coronary syndrome


Study	All CVD		Adjusted factors in multivariate analysis	Definitions of CVD
	Events occurred during follow-up period	RR (95% CI) (or OR [95% CI])		
Fasano, 2017, Italy ²⁹	16	0.27 (0.08-0.86)	ASA treatment, hypertension, aPL positivity, cumulative damage at last visit, hypercholesterolaemia	Angina, myocardial infarction, heart failure, transient ischaemic attack, stroke or peripheral arterial thrombosis
Hung, 2017, China ³²	1253	1.06 (0.76-1.49)	Age, sex or the preexisting cardiovascular comorbidities (hypertension, diabetes, hyperlipidemia)	Acute myocardial infarction, other acute and subacute forms of ischaemic heart disease, old myocardial infarction, angina pectoris, other form of chronic ischemic heart disease
Roman, 2003, USA ²³	-	0.49 (0.21-1.12)	Age, the age at diagnosis, the duration of disease, the damage-index score, the presence of anti-Sm antibodies and significant treatment variables	Atherosclerosis (carotid plaque)
Bessant, 2006, UK ¹⁶	-	0.14 (0.02-0.62)	Unadjusted	Myocardial infarction, angina, cerebral infarctior or peripheral vascular disease
de Leeuw, 2006, Netherlands ¹⁷	-	1.05 (0.32-3.51)	Unadjusted	Ischemic heart disease, cerebrovascular accident or peripheral vascular disease
Van-Halm, 2006, Netherlands ²⁵	-	0.45 (0.10-2.04)	Age, gender, smoking, rheumatoid arthritis duration, hypertension, diabetes and hypercholesterolemia	Coronary artery disease (myocardial infarction, a coronary artery by-pass graft procedure, a percutaneous transluminal coronary angioplasty o ischemic abnormalities on ECG), cerebral arteria disease (cerebral vascular accident, a transient

Study	All CVD		Adjusted factors in multivariate analysis	Definitions of CVD
-	Events occurred during follow-up period	RR (95% CI) (or OR [95% CI])	_	
	pence			peripheral arterial disease (aneurysm of the
				thoracic and/or abdominalis aorta, a peripheral arterial by-pass operation or amputation of the (lower) leg)
Becker-Merok,	44	0.19 (0.08-0.47)	Unadjusted	Myocardial infarction,
2009, Norway ¹⁵				angina pectoris
				, intermittent claudication or cerebrovascular
				accident
Gustafsson, 2009, Sweden ¹⁸	24	0.62 (0.22-1.76)	-	-
Pons-Estel, 2009,	43	1.30 (0.50-3.41)	The directed	Angina, coronary artery bypass surgery, heart
USA ²²			Unadjusted	failure or myocardial infarction
Yang, 2012, China ²⁶	-	0.067(0.01-0.73)	Reduced levels of C4, the presence of anti-Sm antibody, proteinuria, elevated levels of AST and serum creatinine	Myocardial infarction, angina, cerebral infarction, peripheral atherosclerosis, pulmonary arterial hypertension or valvular heart disease
Kao, 2013, USA ³⁰	17	0.49 (0.18-1.31)	Unadjusted	Myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, fatal cardiac arrest, and/or cerebrovascula accident
Li, 2017, China ³¹	256	0.19(0.05-0.71)	Age, gender, disease duration, age of RA onset,	Acute coronary syndromes, chronic coronary hear


Study	Study All CVD		Adjusted factors in multivariate analysis	Definitions of CVD	
	Events	RR (95% CI) (or			
	occurred	OR [95% CI])			
	during				
	follow-up				
	period				
			hypertension, diabetes mellitus, smoking,	disease, ischemic and hemorrhagic stroke,	
			hyperlipidemia, rheumatoid nodules, anemia	peripheral arterial reconstructive surgery, limb	
				amputation, or an ankle brachial pressure index	
				(ABPI) <0.50	

Abbreviations: aPL, antiphospholipid antibodies; AST, aspartate transaminase; CI, confidence interval; C4, complement component 4; CVD, cardiovascular disease; OR, odds ratio; RA, rheumatoid arthritis; RR, relative risk; SELENA, safety of estrogens in lupus erythematosus national assessment; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index instrument score. Supplementary figure 1. Sensitivity analysis excluding unadjusted RR in HR/RR-






Supplementary figure 2. Sensitivity analysis excluding unadjusted OR in OR-




reporting studies.

Supplementary figure 3. Sensitivity analysis using quality-effects model in HR/RR-reporting studies.





Supplementary figure 4. Sensitivity analysis using quality-effects model in OR-



reporting studies.

Supplementary figure 5. Funnel graph in HR/RR-reporting studies.





Supplementary figure 6. Funnel graph in OR-reporting studies.